Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Agios has FDA-approved mitapivat products, an early AQVESME thalassemia launch and more than $1.0B of cash and marketable securities. The diligence question is whether prescription growth and pipeline catalysts can outpace a quarterly expense base above $130M.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
SEC filings, financial facts, source resources, and Goglides workspace context for Redwire Corporation.
OpenRedwire is usually described as a space infrastructure company. But after separating its latest results by segment, I think that description misses the most important part of the $RDW story. In Q1 2026, Redwire’s Space division generated about **54% of total r
OpenA hidden-identity GoGlides receipts explainer on Redwire's backlog, defense-UAS wins, cash flow, and dilution risk.
OpenRedwire Corporation has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenRedwire has fresh space and drone headlines, but the real RDW proof gate is whether record backlog converts into profitable revenue and cash without new dilution pressure.
OpenGitLab reported FY2026 revenue of $955.2 million, gross profit of $834.5 million, operating loss of $70.5 million and operating cash flow of $232.9 million. The setup depends on DevSecOps adoption, platform consolidation, gross-margin durability, operating dis
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenAlpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, s
OpenTag facets appear after tag usage counts are rebuilt.